Synthetic Biology-Driven Engineering of Gut Microbiota for Precision Modulation of Host Metabolome in Metabolic Syndrome
Keywords:
Synthetic biology, Gut microbiota, Metabolic syndrome, Microbial therapeutics, Host metabolome, Engineered microbes, Systems biologyAbstract
Metabolic syndrome, a multifactorial disorder characterized by insulin resistance, dyslipidemia, hypertension, and central obesity, is tightly linked with gut microbiota dysbiosis. Advances in synthetic biology offer innovative strategies to reprogram gut microbes for targeted metabolic interventions. This paper explores how engineered microbial consortia can be leveraged for precision modulation of the host metabolome in metabolic syndrome. Emphasis is placed on microbial chassis design, metabolite biosensing, and feedback-controlled therapeutic delivery. Experimental data and modeling underscore the therapeutic potential of microbial engineering to address metabolic syndrome’s complexity.
References
Turnbaugh, P. J., et al. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031.
Cani, P. D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56(7), 1761–1772.
Louis, P., & Flint, H. J. (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiology Letters, 294(1), 1–8.
Ridaura, V. K., et al. (2013). Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341(6150), 1241214.
Riglar, D. T., et al. (2017). Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nature Biotechnology, 35(7), 653–658.
Mimee, M., et al. (2015). Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut Microbiota. Cell Systems, 1(1), 62–71.
Charbonneau, M. R., et al. (2020). Engineering the microbiome for disease treatment and prevention. Cell Host & Microbe, 28(5), 662–678.
Danino, T., et al. (2015). Programmable probiotics for detection of cancer in urine. Science Translational Medicine, 7(289), 289ra84.
Hwang, I. Y., et al. (2017). Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nature Communications, 8, 15028.
Kurtz, C. B., et al. (2019). An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Science Translational Medicine, 11(475), eaau7975.
Downloads
Published
Issue
Section
License
Copyright (c) -1 Joel Samuel (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
